Novartis Pharmeceuticals Ltd.

Authors Avatar

        -  –        Aman Mutneja                 

TO            : Martin Savery

FROM      : Aman Mutneja

REF          : Novartis

INTRODUCTION:

This report written on the 16th November 2002 has the following information about Novartis pharmaceuticals:

  • The history of the company.
  • The objectives of the company.
  • The corporate structure and the legal identity of the company.
  • The culture of the company.
  • The impact of technology.
  • The internal structure of Novartis.
  • The management structure and its style.

This report was prepared keeping in mind a few objectives:

  • To understand how a company runs.
  • To familiarise as to how the company plans its strategies.
  • To have a practical knowledge of the working of a business.
  • To understand how a company plans its structure.

All of this is followed by the conclusions and recommendations as to how the company can improve/expand its business.

The entire report on Novartis is based on the findings by primary research and secondary research.

The secondary research included the college notes, the Internet, the information mailed by the company.

This was followed by the primary research that included personal interview of the manager of the company, discussion and sharing of information with the college colleagues.

Introduction to Novartis:

      Novartis is a world leader in the research and development of products to protect and improve health and well being. The name Novartis, derived from the Latin novae artes, meaning "new skills," reflects the company’s commitment to focus on research and development to bring innovative new products to the society they serve. They are a scientific and educational charity, formed in 1949 by the Swiss company Ciba (now Novartis).  They have a mission to bring value to their patients and customers. They want to have a positive impact on people's lives and to discover, develop and successfully market innovative products to cure diseases and enhance the quality of life. In addition, they want to provide a shareholder return that reflects their outstanding performance. They also want to build a reputation for an exciting workplace where people can realize the company’s professional ambitions and where creativity is encouraged. They have their objectives based on the following core values:

External focus:

“They try to keep a step ahead of what their customers want and a close eye on what their competitors are doing.”

Innovation:

“They have the patience and the skills to gain professional competence and adopt a wider perspective. It is from this platform that they take the initiative, take calculated risks, and set out to do new things in new ways.”

People:

“The future of the company is in the hands of the company itself. They have excellent people committed to values such as candor, trust and integrity. Through teamwork and cooperation, they enhance learning throughout the organization.”

Performance:

“The management sets ambitious targets, benchmarking themselves against peers, and striving always for 'best practice' levels of performance. The company look to reduce bureaucracy and risk-averse behaviour.”

In addition, Novartis wants to be known for being a responsible corporate citizen. They do everything they can to operate in a manner that is sustainable: economically, socially, and environmentally - in the best interest of long-term success for their enterprise. In addition, they place a premium on dealing fairly with their employees, the commercial partners, the government authorities and the customers. Their Policy on Corporate Citizenship includes the principles of the UN Global Compact while their Code of Conduct covers ethical and legal behaviour, including consideration of stakeholder interests, professionalism, and fair, courteous and respective treatment of their employees. Their Health, Safety and Environment Protection (HSE) Policies expresses their commitment for conducting their activities with respect for the health and safety of their stakeholders and the protection of the environment. The principles articulated in these documents are binding for all the company associates, and all managers are required to monitor compliance.”

Locations:

Novartis began with its headquarters in Basel, Switzerland; it innovates for the benefit of its customers. They operate through 360 affiliates in 140 countries and offer their products through their Pharmaceuticals, Generics, Consumer Health, CIBA Vision, Animal Health, and Business Development & Licensing Sectors.

The principal companies operate in the following countries:

Novartis in the United Kingdom:

In the UK, Novartis is one of the largest suppliers of medicines to the NHS and is committed to improving health and well being through innovation.

Novartis employees and operations in the UK make a vital contribution to the overall Novartis commitment to improve health and well being all over the world.

Novartis medicines are used to make organ transplantation possible and are used in the treatment of cardiovascular disease, skin diseases, cancer, Alzheimer's disease and schizophrenia.

Every day, CIBA Vision contact lenses and eye care products help make a difference.

Their “over the counter” medicines and household brands are present in millions of homes in the UK, relieving colds, coughs and meeting daily nutritional needs.

Pet owners care for their cats and dogs with the animal health range.

Scientists in Horsham and London are leading the company’s worldwide research in respiratory disease and chronic pain relief, respectively.

They have a broad range of products, supported by one of the most promising sets of potential new treatments currently in development in the pharmaceutical industry. In the UK alone, Novartis invests around £1 million each week on research and development of new treatments.

18 per cent of sales are invested in research and development and there are excellent pharmaceutical products in the pipeline.

The diagram above shows as to what are the products they expect to launch in the near future in the United Kingdom.

The UK ranks amongst the top four countries for R&D spend by Novartis and is the strategic location for a new, excellent centre dedicated to research into new treatments for respiratory disease. Known as the Novartis Horsham Research Centre (NHRC), it marks an investment of over £40 million.

The NRRC also hosts international pre-clinical and clinical operations for other therapeutic research areas. Each major step of the pharmaceutical product development process is undertaken at Horsham, from compound discovery and research right through to manufacturing.

In addition, the Novartis Institute for Medical Sciences, based at University College, London is researching new ways to relieve chronic pain.

On April 26th 2001, Novartis UK celebrated their fifth Community Partnership Day when Novartis associates around the world left their workplaces to lend a hand wherever they were needed.

The staff/employees in the United Kingdom:

Employees:

Novartis has more employees in Europe than in any part of the world. In the United Kingdom alone Novartis has a staff of over 65,000.

Headquarters in the United Kingdom:

 Novartis Pharmaceuticals UK Ltd,

 Frimley Business Park,

 Frimley,

 Camberley,

 Surrey, GU16 5SG
Tel: 01276 692255
Fax: 01276 692508

History of the company:

How it all started?

1970
Ciba and Geigy merge to form Ciba-Geigy Ltd. In 1992, the company is renamed Ciba in line with the introduction of a new logo.

1975
Sandoz
advances into the seeds market with the acquisition of the American Rogers Seed Co., followed by the acquisition of Northrup King in 1976, the Dutch Zaadunie Group in 1980 and the Swedish seeds company Hilleshög in 1989.

1987
CIBA Vision is set up as a separate business unit.

Join now!

1985

Acquisition of the American Master Builders, Inc. and the Japanese Nisso Master Builders K.K.; creation of the construction chemicals division by Sandoz.

1990
Sandoz is transformed into a holding company.

1994
Ciba and Chiron form a strategic partnership.

1995
With the foundation of Clariant Ltd., Sandoz separates out its Special Chemicals business, thus focusing on Pharma and Nutrition.

7 March 1996

The news struck the business world like a thunderbolt. Sandoz and Ciba, two proud Swiss-based companies with almost three hundred years of tradition, have agreed to become one. The creation of Novartis, as the new company was called, was at ...

This is a preview of the whole essay